Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07570069 · ClinicalTrials.gov registry record · Phase 1
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07570069 is a Phase 1 study that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 18 participants.
The verdict
NCT07570069, a Phase 1 study, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.
Interventions
- DRUG Suzetrigine
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-07 |
| Est. Completion | 2026-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07570069
The ClinicalTrials.gov registry entry for NCT07570069 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Suzetrigine is the first listed.
NCT07570069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07570069 about?
NCT07570069 is a clinical study titled "Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants". The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of ef...
What is the current status of trial NCT07570069?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-05-07. Estimated completion is 2026-07-11.
What interventions are being tested in trial NCT07570069?
The interventions under investigation include: Suzetrigine (DRUG), Efavirenz (DRUG).
Who is sponsoring clinical trial NCT07570069?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.